28 April 2025 - Australian patients with the most common form of lymphoma will for the first time have access to affordable, at-home treatment options after the federal subsidisation of an injectable immunotherapy.

Epcoritimab is a treatment for diffuse large B-cell lymphoma, a form of non-Hodgkin's lymphoma affecting 2000 Australians annually and characterised by its aggressive growth.

Read The Australian article